Enbrel (Etanercept) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The enbrel (etanercept) market size has grown strongly in recent years. It will grow from $17.7 million in 2025 to $18.8 million in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to increasing prevalence of autoimmune disorders, availability of biologic treatment options, expansion of rheumatology care services, growing acceptance of injectable biologics, improved patient awareness.

The enbrel (etanercept) market size is expected to see strong growth in the next few years. It will grow to $23.64 million in 2030 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to increasing competition from biosimilars, rising demand for cost-effective biologic therapies, expansion of home-based treatment models, growing focus on value-based healthcare, increasing innovation in biologic drug delivery systems. Major trends in the forecast period include increasing adoption of biosimilar tnf inhibitors, rising focus on patient self-administration devices, growing use of long-term maintenance therapy, expansion of autoimmune disease indications, enhanced emphasis on treatment adherence.

The increasing prevalence of autoimmune conditions is expected to drive the growth of the enbrel (etanercept) market in the coming years. Autoimmune conditions arise when the immune system mistakenly attacks the body's own healthy tissues. This rising prevalence is influenced by factors such as genetic susceptibility, the hygiene hypothesis, environmental triggers, and improved diagnosis and awareness. Enbrel is effective in managing several autoimmune disorders, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. It functions by inhibiting tumor necrosis factor-alpha (TNF-α), a key protein involved in immune and inflammatory responses, thereby reducing inflammation, easing symptoms, and slowing disease progression. For example, in June 2024, data published by the Australian Institute of Health and Welfare, a national agency for health information and statistics in Australia, indicated that in 2022, approximately 514,000 Australians (2%) were living with rheumatoid arthritis. This accounted for 2% of the total disease burden and 16% of the musculoskeletal disease burden in 2023. It also resulted in 1,322 deaths (5.1 per 100,000), representing 0.7% of all deaths. Consequently, the rising prevalence of autoimmune conditions is expected to propel the growth of the enbrel (etanercept) market moving forward.

Major companies operating in the Enbrel (etanercept) market are developing innovative products, such as TNF inhibitors, to reduce inflammation and modulate immune system activity. A TNF inhibitor is a biologic therapy that targets and blocks tumor necrosis factor (TNF), a protein that plays a central role in inflammation, to help manage autoimmune diseases. For example, in October 2023, Amgen Inc., a US-based biotechnology company, announced U.S. Food and Drug Administration approval for Enbrel (etanercept) for the treatment of children aged two and older with active juvenile psoriatic arthritis (JPsA). The biologic medication is used to manage autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. It works by blocking tumor necrosis factor (TNF), a protein that triggers inflammation and immune responses, helping to reduce symptoms such as joint swelling and pain. Administered via a weekly subcutaneous injection, Enbrel can be used alone or in combination with other medications, such as methotrexate.

In December 2023, Intas Pharmaceuticals Ltd., an India-based pharmaceutical company that produces biosimilar drugs for etanercept, entered into an exclusive licensing agreement with mAbxience for the commercialization of an etanercept biosimilar. Through this partnership, Intas aims to enhance its global biosimilar portfolio and broaden access to high-quality treatments for autoimmune diseases in over 150 countries, including key markets such as Europe and the United States. mAbxience is a Spain-based company focused on the development, production, and commercialization of biopharmaceuticals.

Major companies operating in the enbrel (etanercept) market are Amgen Inc, Pfizer Inc.

North America was the largest region in the enbrel (etanercept) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the enbrel (etanercept) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the enbrel (etanercept) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the enbrel (etanercept) market by increasing costs of imported biologic raw materials, formulation excipients, cold-chain packaging, and sterile manufacturing equipment. Biologic drug manufacturing in North America and Europe is most affected due to reliance on globally sourced inputs, while Asia-Pacific faces pricing pressure in biosimilar production. These tariffs are contributing to higher manufacturing and distribution costs. However, they are also encouraging localized biologic manufacturing, regional supply chain resilience, and strategic investments in domestic biologics production capacity.

The enbrel (etanercept) market research report is one of a series of new reports that provides enbrel (etanercept) market statistics, including enbrel (etanercept) industry global market size, regional shares, competitors with a enbrel (etanercept) market share, detailed enbrel (etanercept) market segments, market trends and opportunities, and any further data you may need to thrive in the enbrel (etanercept) industry. This enbrel (etanercept) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Enbrel (etanercept) is a biologic drug used to manage several autoimmune disorders by blocking the activity of tumor necrosis factor (TNF), a protein that contributes significantly to inflammation. It is a synthetic version of a naturally occurring protein in the body, engineered to attach to TNF and stop it from binding to its receptors, thereby decreasing inflammation. It is usually given through subcutaneous injection, either by a healthcare professional or by patients themselves at home.

The main forms of enbrel (etanercept) include brand medications and biosimilar versions. Enbrel is a biologic drug containing etanercept, used to manage autoimmune disorders such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis by blocking tumor necrosis factor (TNF). It is available in both liquid solution and powder for injection forms and is used for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis.

The enbrel (etanercept) market consists of sales of injections, cooler packs, reconstitution kit and related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.